Immunic Stock Net Income
| IMUX Stock | USD 1.24 0.01 0.81% |
Immunic fundamentals help investors to digest information that contributes to Immunic's financial success or failures. It also enables traders to predict the movement of Immunic Stock. The fundamental analysis module provides a way to measure Immunic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Immunic stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | -93.6 M | -88.9 M | |
| Net Loss | -93.6 M | -98.3 M | |
| Net Loss | -108.4 M | -102.9 M | |
| Net Loss | (2.11) | (2.22) | |
| Net Income Per E B T | 1.15 | 0.86 |
Immunic | Net Income |
Immunic Company Net Income Analysis
Immunic's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Immunic Net Income | (93.61 M) |
Most of Immunic's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Immunic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Immunic Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for Immunic is extremely important. It helps to project a fair market value of Immunic Stock properly, considering its historical fundamentals such as Net Income. Since Immunic's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Immunic's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Immunic's interrelated accounts and indicators.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Immunic Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, Immunic reported net income of (93.61 Million). This is 127.43% lower than that of the Biotechnology sector and 233.64% lower than that of the Health Care industry. The net income for all United States stocks is 116.39% higher than that of the company.
Immunic Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Immunic's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Immunic could also be used in its relative valuation, which is a method of valuing Immunic by comparing valuation metrics of similar companies.Immunic is currently under evaluation in net income category among related companies.
Immunic Current Valuation Drivers
We derive many important indicators used in calculating different scores of Immunic from analyzing Immunic's financial statements. These drivers represent accounts that assess Immunic's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Immunic's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 74.9M | 239.5M | 226.4M | 44.5M | 51.2M | 48.7M | |
| Enterprise Value | 46.1M | 112.7M | 140.1M | (60.6M) | (69.7M) | (66.2M) |
Immunic Institutional Holders
Institutional Holdings refers to the ownership stake in Immunic that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Immunic's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Immunic's value.| Shares | Sierra Summit Advisors Llc | 2023-12-31 | 324.8 K | Cowen And Company, Llc | 2023-12-31 | 317.1 K | Soleus Capital Management, L.p. | 2023-12-31 | 300 K | Innovis Asset Management Llc | 2023-09-30 | 272.5 K | Schonfeld Strategic Advisors Llc | 2023-09-30 | 238.7 K | Northern Trust Corp | 2023-12-31 | 164.4 K | Two Sigma Advisers, Llc | 2023-12-31 | 147.4 K | State Street Corporation | 2023-12-31 | 125.8 K | Two Sigma Investments Llc | 2023-12-31 | 116.5 K | Rtw Investments, Llc | 2023-12-31 | 4.3 M | Gratus Capital Llc | 2023-12-31 | 1.9 M |
Immunic Fundamentals
| Return On Equity | -1.31 | ||||
| Return On Asset | -0.68 | ||||
| Current Valuation | 66.17 M | ||||
| Shares Outstanding | 89.93 M | ||||
| Shares Owned By Insiders | 7.72 % | ||||
| Shares Owned By Institutions | 58.08 % | ||||
| Number Of Shares Shorted | 3.03 M | ||||
| Price To Earning | (6.65) X | ||||
| Price To Book | 4.48 X | ||||
| EBITDA | (99.11 M) | ||||
| Net Income | (93.61 M) | ||||
| Cash And Equivalents | 72.77 M | ||||
| Cash Per Share | 1.85 X | ||||
| Total Debt | 1.33 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 7.53 X | ||||
| Book Value Per Share | 0.64 X | ||||
| Cash Flow From Operations | (70.83 M) | ||||
| Short Ratio | 5.23 X | ||||
| Earnings Per Share | (2.11) X | ||||
| Price To Earnings To Growth | (0.03) X | ||||
| Target Price | 11.5 | ||||
| Number Of Employees | 77 | ||||
| Beta | 1.95 | ||||
| Market Capitalization | 111.51 M | ||||
| Total Asset | 54.3 M | ||||
| Retained Earnings | (410.89 M) | ||||
| Working Capital | 27.8 M | ||||
| Current Asset | 32.33 M | ||||
| Current Liabilities | 4.73 M | ||||
| Net Asset | 54.3 M |
About Immunic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Immunic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Immunic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Immunic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Immunic in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Immunic's short interest history, or implied volatility extrapolated from Immunic options trading.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Immunic Piotroski F Score and Immunic Altman Z Score analysis. For more information on how to buy Immunic Stock please use our How to Invest in Immunic guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Immunic Stock analysis
When running Immunic's price analysis, check to measure Immunic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunic is operating at the current time. Most of Immunic's value examination focuses on studying past and present price action to predict the probability of Immunic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunic's price. Additionally, you may evaluate how the addition of Immunic to your portfolios can decrease your overall portfolio volatility.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Immunic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunic. If investors know Immunic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.11) | Return On Assets (0.68) | Return On Equity (1.31) |
The market value of Immunic is measured differently than its book value, which is the value of Immunic that is recorded on the company's balance sheet. Investors also form their own opinion of Immunic's value that differs from its market value or its book value, called intrinsic value, which is Immunic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunic's market value can be influenced by many factors that don't directly affect Immunic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immunic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.